Abstract:Numerous peptides inhibit the entry of enveloped viruses into cells. Some of these peptides have been shown to inhibit multiple unrelated viruses. We have suggested that such broad-spectrum antiviral peptides share a property called interfacial activity; they are somewhat hydrophobic and amphipathic, with a propensity to interact with the interfacial zones of lipid bilayer membranes. In this study, we further tested the hypothesis that such interfacial activity is a correlate of broad-spectrum antiviral activity. In this study, several families of peptides, selected for the ability to partition into and disrupt membrane integrity but with no known antiviral activity, were tested for the ability to inhibit multiple diverse enveloped viruses. These include Lassa pseudovirus, influenza virus, dengue virus type 2, herpes simplex virus 1, and nonenveloped human adenovirus 5. Various families of interfacially active peptides caused potent inhibition of all enveloped viruses tested at low and submicromolar concentrations, well below the range in which they are toxic to mammalian cells. These membrane-active peptides block uptake and fusion with the host cell by rapidly and directly interacting with virions, destabilizing the viral envelope, and driving virus aggregation and/or intervirion envelope fusion. We speculate that the molecular characteristics shared by these peptides can be exploited to enable the design, optimization, or molecular evolution of novel broad-spectrum antiviral therapeutics.IMPORTANCE New classes of antiviral drugs are needed to treat the ever-changing viral disease landscape. Current antiviral drugs treat only a small number of viral diseases, leaving many patients with established or emerging infections to be treated solely with supportive care. Recent antiviral peptide research has produced numerous membrane-interacting peptides that inhibit diverse enveloped viruses in vitro and in vivo Peptide therapeutics are becoming more common, with over 60 FDA-approved peptides for clinical use. Included in this class of therapeutics is enfuvirtide, a 36-residue peptide drug that inhibits HIV entry/fusion. Due to their broad-spectrum mechanism of action and enormous potential sequence diversity, peptides that inhibit virus entry could potentially fulfill the need for new antiviral therapeutics; however, a better understanding of their mechanism is needed for the optimization or evolution of sequence design to combat the wide landscape of viral disease.

Expanding horizons of iminosugars as broad-spectrum anti-virals: mechanism, efficacy and novel developments

Iminosugars As Immunomodulating Agents: Synthesis And Biological Activities Of 1-Deoxynojirimycin And Related Compounds

Recent advances in antiviral activities and potential mechanisms of sulfated polysaccharides

Design, Synthesis and Biological Evaluation of Gentiopicroside Derivatives As Potential Antiviral Inhibitors.

Iminosugars counteract the downregulation of the interferon γ receptor by dengue virus

ChemInform Abstract: Iminosugars As Immunomodulating Agents: Synthesis and Biological Activities of 1‐deoxynojirimycin and Related Compounds

Design of novel broad-spectrum antiviral nucleoside analogues using natural bases ring-opening strategy

Discovery of ligustrazine and chalcone derivatives as novel viral nucleoprotein nuclear export inhibitors against influenza viruses

Multivalent Pyrrolidine Iminosugars: Synthesis and Biological Relevance

Discovery, Optimization and Target Identification of Novel Potent Broad-Spectrum Antiviral Inhibitors.

Biological Evaluation of Uridine Derivatives of 2-Deoxy Sugars as Potential Antiviral Compounds against Influenza A Virus

Antiviral Activity of Isoimperatorin Against Influenza A Virus in vitro and its Inhibition of Neuraminidase

Design, synthesis, and biological activity of a novel series of 2-ureidonicotinamide derivatives against influenza A virus

Promising Role of Emodin as Therapeutics to Against Viral Infections

Advances in Influenza Virus Sialidase Inhibitors

Broad-Spectrum Antiviral Entry Inhibition by Interfacially Active Peptides

Identification of novel broad-spectrum antiviral drugs targeting the N-terminal domain of the FIPV nucleocapsid protein

Development of Broad-Spectrum Antiviral Agents—Inspiration from Immunomodulatory Natural Products

A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses

Design, synthesis and biological evaluation of novel L-ascorbic acid-conjugated pentacyclic triterpene derivatives as potential influenza virus entry inhibitors.

Synthetic N-alkylated iminosugars as new potential immunosuppressive agents.